Newtopia Reports First Quarter 2023 Financial Results
- Ongoing cost optimization to achieve profitability in 2023
- Q1 2023 gross margin (non IFRS)1 up 1300 basis points year over year
- Quarterly conference call scheduled for
May 30, 2023 at5 pm ET
- Revenue of
$2.65 million , as compared to$2.87 million . - Gross profit margin1 of 60%, as compared to 47%.
"We continued to see momentum in gross profit and operating expense improvements in the first quarter as we implement the strategic plan we laid out in 2022," said
Ruby continued, "We look forward to seeing the benefit of several recent multi-year contract renewals with large clients that will further enhance our revenue and profitability in the second half of the year. As a result of implementing one of these multi-year contract renewals for a large client during the quarter, we identified hundreds of participants who had made material health improvements using our platform, providing further evidence that our solution is highly engaging and effective. For this group, we made some important value-based changes to our definition of engaged participants that we intend to further improve their habits. While this change had a declining impact on our first quarter revenue, we anticipate that we will be able to adjust to this higher engagement level commitment in successive quarters as we transition additional participant engagement behaviors into habits.
In addition to organic growth, our pipeline of new business with self-insured employers and innovative health plans remains robust. Opportunities from leading macro drivers for our industry, including the growing popularity of, and commercial interest in, GLP-1 medications for diabetes and weight management, alongside growth in advanced primary care are creating a vast new landscape of possibilities for habit change platforms like Newtopia. I continue to believe that there is no better time to invest in primary prevention habit change, and Newtopia is at the forefront of preventing, reversing and slowing chronic disease."
Revenue for the three months ended
Non-IFRS gross profit for the first quarter 2023 totaled
Operating expenses2 for the three months ended
The Company ended the first quarter 2023 with approximately
Newtopia continues to anticipate top and bottom-line year-over-year growth in 2023. In addition, due to continued strategic expense management including additional cuts made in the first quarter, Newtopia anticipates that the Company is currently on a clear path to EBITDA and cash flow positive within 2023. Profitability is anticipated to build throughout the year, with the bottom line improving incrementally each quarter.
The Company will host a conference call today at
A replay of the conference call will be available through
Newtopia is a tech-enabled habit change provider focused on disease prevention and reducing the cost of care for health insurers. As a provider of whole person care, we prevent, reverse and slow the progression of chronic disease while enriching mental health, resilience and overall human performance. Newtopia's programs leverage genetic, social and behavioral insights to create individualized prevention programs with a focus on type 2 diabetes, heart disease, stroke and weight. With a person-centered approach that combines virtual care, digital tools, connected devices and actionable data science, Newtopia delivers sustainable clinical and financial outcomes. To learn more, visit newtopia.com , LinkedIn or Twitter.
This news release contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, and forward looking statements, within the meaning of applicable
Should any factor affect Newtopia's in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, Newtopia does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and Newtopia undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
The Company's financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS"). Management uses certain non-IFRS measures, which are defined in the appropriate sections of this press release, to better assess the Company's underlying performance. These measures are reviewed regularly by management and the Company's Board of Directors in assessing the Company's performance and in making decisions about ongoing operations. In addition, we use certain non-IFRS measures to determine the components of management compensation. We believe that these measures are also used by investors as an indicator of the Company's operating performance. Readers are cautioned that these terms are not recognized IFRS measures and do not have a standardized meaning under IFRS and should not be construed as alternatives to IFRS terms, such as net income.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Key Financial Measures and Schedule of Non-GAAP Reconciliations
Gross Profit Information [1]
Three Months Ended | |||
2023 | 2022 | ||
$ | $ | ||
Revenue | 2,648,657 | 2,866,714 | |
Cost of revenue | (1,275,682) | (1,517,836) | |
Gross profit | 1,372,975 | 1,348,878 | |
Add amortization of intangible asset | 206,514 | - | |
Non-IFRS adjusted gross profit | 1,579,489 | 1,348,878 | |
Gross profit margin | 52 % | 47 % | |
Non-IFRS adjusted gross profit margin | 60 % | 47 % | |
Reconciliation of Total Operating Expenses to Adjusted Operating Expenses [2]
Three Months Ended | |||
2023 | 2022 | ||
$ | $ | ||
Total expenses | 2,745,802 | 2,976,571 | |
Add (Subtract) | |||
Share-based compensation | (93,290) | (132,508) | |
Depreciation of property and equipment | (1,549) | (14,380) | |
Depreciation of right-of-use asset | - | (46,195) | |
Interest on lease obligations | (12,590) | (22,979) | |
Interest and accretion expense | (169,695) | (97,290) | |
Finance charges | (109,648) | (37,110) | |
Capitalized borrowing costs | - | 29,000 | |
Foreign exchange loss | (18,272) | (15,033) | |
Amortization of deferred finance charges | (33,815) | (58,800) | |
Adjusted operating expenses | 2,306,943 | 2,581,276 | |
EBITDA [3]
Three Months Ended | |||
2023 | 2022 | ||
$ | $ | ||
Non-IFRS gross profit | 1,579,489 | 1,348,878 | |
Adjusted operating expenses | (2,306,943) | (2,581,276) | |
EBITDA | (727,454) | (1,232,398) | |
NEWTOPIA INC.
Condensed Interim Statements of Financial Position (Unaudited)
As at
(Expressed in Canadian Dollars)
2023 | 2022 | |
(Unaudited) | (Audited) | |
$ | $ | |
Assets | ||
Current assets | ||
Cash | 338,370 | 345,950 |
Trade and other receivables | 1,469,887 | 1,557,640 |
Contract asset | 55,400 | 190,000 |
Prepaid expenses and deposits | 183,731 | 205,843 |
Inventories | 214,976 | 325,571 |
Deferred costs | 56,954 | 76,269 |
2,319,318 | 2,701,273 | |
Property and equipment | 7,602 | 8,052 |
Intangible asset | 3,028,849 | 3,235,363 |
5,355,769 | 5,944,688 | |
Liabilities | ||
Current liabilities | ||
Trade and other payables | 2,320,039 | 2,584,039 |
Credit facility | 4,434,191 | 4,823,545 |
Lease obligations | 307,915 | 544,700 |
Deferred revenue | 48,185 | 48,185 |
Debentures | 2,456,046 | 2,409,103 |
9,566,376 | 10,409,572 | |
Debentures | 1,096,749 | 1,068,772 |
10,663,125 | 11,478,344 | |
Equity/Deficit | ||
Common shares | 48,882,767 | 47,978,992 |
Contributed surplus | 13,556,801 | 12,861,449 |
Deficit | (67,746,924) | (66,374,097) |
(5,307,356) | (5,533,656) | |
5,355,769 | 5,944,688 |
NEWTOPIA INC.
Condensed Interim Statements of Loss and Comprehensive Loss (Unaudited)
Three Months Ended
(Expressed in Canadian Dollars)
2023 | 2022 | |
$ | $ | |
Revenue | 2,648,657 | 2,866,714 |
Cost of revenue | 1,275,682 | 1,517,836 |
Gross profit | 1,372,975 | 1,348,878 |
Operating expenses | ||
Technology and development | 922,065 | 806,295 |
Sales and marketing | 426,170 | 644,211 |
General and administrative | 958,708 | 1,130,770 |
Share–based compensation | 93,290 | 132,508 |
Depreciation of property and equipment | 1,549 | 14,380 |
Depreciation of right–of–use asset | – | 46,195 |
2,401,782 | 2,774,359 | |
Other expenses (income) | ||
Interest on lease obligations | 12,590 | 22,979 |
Interest and accretion expense | 169,695 | 97,290 |
Finance charges | 109,648 | 37,110 |
Capitalized borrowing costs | – | (29,000) |
Foreign exchange loss | 18,272 | 15,033 |
Amortization of deferred finance charges | 33,815 | 58,800 |
344,020 | 202,212 | |
Net loss and comprehensive loss | (1,372,827) | (1,627,693) |
NEWTOPIA INC.
Condensed Interim Statements of Changes in Equity (Unaudited)
Three Months Ended
(Expressed in Canadian Dollars)
Common Shares | Contributed Surplus |
Deficit |
Total | |
$ | $ | $ | $ | |
Balance, | 47,978,992 | 12,861,449 | (66,374,097) | (5,533,656) |
Net loss and comprehensive loss | – | – | (1,372,827) | (1,372,827) |
Share–based compensation | – | 93,290 | – | 93,290 |
Settlement of related party payable | – | 38,542 | – | 38,542 |
Private placement offering of Units, net of issuance costs | 930,218 | 537,077 | – | 1,467,295 |
Compensation options | (26,443) | 26,443 | – | - |
Balance, | 48,882,767 | 13,556,801 | (67,746,924) | (5,307,356) |
Balance, | 45,177,120 | 11,652,200 | (58,673,634) | (1,844,314) |
Net loss and comprehensive loss | – | – | (1,627,693) | (1,627,693) |
Share–based compensation | – | 132,508 | – | 132,508 |
Settlement of related party payable | – | 23,485 | – | 23,485 |
Balance, | 45,177,120 | 11,808,193 | (60,301,327) | (3,316,014) |
Condensed Interim Statements of Cash Flows (Unaudited)
Three Months Ended
(Expressed in Canadian Dollars)
2023 | 2022 | |
$ | $ | |
Cash flows used in operating activities | ||
Net loss and comprehensive loss | (1,372,827) | (1,627,693) |
Items not involving cash: | ||
Depreciation of property and equipment | 1,549 | 14,380 |
Depreciation of right–of–use asset | – | 46,195 |
Amortization of intangible asset | 206,514 | – |
Capitalized borrowing costs | – | (29,000) |
Amortization of deferred finance charges | 33,815 | 58,800 |
Accretion expense | 74,920 | 46,390 |
Interest on lease obligations | 12,590 | 22,979 |
Stock–based compensation | 93,290 | 132,508 |
(950,149) | (1,335,441) | |
Change in non–cash working capital | ||
Trade and other receivables | 87,753 | (190,564) |
Prepaid expenses and deposits | 22,112 | 74,638 |
Inventories | 110,595 | (68,233) |
Trade and other payables | (225,458) | 668,722 |
Contract asset/liability | 134,600 | 137,554 |
Deferred revenue | – | (4,582) |
(820,547) | (717,906) | |
Cash flows used in investing activities | ||
Purchase of property and equipment | (1,099) | (1,788) |
Intangible asset development costs | – | (448,099) |
(1,099) | (449,887) | |
Cash flows provided by financing activities: | ||
Credit facility withdrawals | 1,415,546 | 2,318,568 |
Credit facility repayments | (1,804,900) | (804,580) |
Credit facility financing costs | (14,500) | (15,381) |
Repayment of lease obligations | (249,375) | (93,971) |
Proceeds from private placement offering of Units, net of cash issuance costs | 1,467,295 | – |
814,066 | 1,404,636 | |
Net change in cash during the period | (7,580) | 236,843 |
Cash, beginning of period | 345,950 | 811,584 |
Cash, end of period | 338,370 | 1,048,427 |
1 | Gross profit is defined as revenue, which is comprised of onboarding |
2 | Adjusted operating expenses consist of all cash-based technology, sales and marketing and administrative expenses. Adjusted operating expense is not a measure of financial performance under IFRS and should not be considered a substitute for total operating expenses, which we believe to be the most directly comparable IFRS measure. |
3 | EBITDA stands for "earnings before interest, tax, depreciation and amortization". Although a commonly used financial metric, EBITDA is not a measure of financial performance under IFRS and should not be considered a substitute for loss from operations which we believe to be the most directly comparable IFRS measure. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/newtopia-reports-first-quarter-2023-financial-results-301837706.html
SOURCE Newtopia Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Lemonade Expands Renters Insurance to Maine
- Skyhawk Therapeutics Announces Expansion of its Global Pivotal FALCON-HD Clinical Trial for SKY-0515 in Huntington's Disease to the United States, Canada and the United Kingdom
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
Twitter, EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share